@entity1793 , @entity12119 , and XXXX .

@entity1 @entity3883 @entity1087 @entity12119 @entity648 @entity409 @entity1793
@entity12119 was used to treat 131 out of 250 @entity1 with @entity1793 over 10 years. Other antimicrobial agents were given to the 119 remaining @entity1 . Thirty-seven @entity1 were @entity1087 before antibiotic treatment was started. @entity1087 developed during treatment in 38 out of 112 @entity1 given @entity12119 (34%) and in two out of 101 @entity1 given other antimicrobials. The incidence of @entity1087 was higher in @entity1 given @entity12119 intravenously (48%) rather than by mouth (13%). @entity1087 appeared within 48 hours after the administration of @entity12119 in 93% of these cases. When the drug was stopped serum @entity648 concentrations fell to normal values within four days in those @entity1 in whom they had been previously normal and who survived the bacteraemic episode. @entity12119 was associated with increasing @entity1087 in 13 of 19 @entity1 (68%) @entity1087 before it was given. In six out of 32 @entity1 who developed @entity1087 while receiving intravenous @entity12119 serum alkaline phosphatase activity was raised suggestive of @entity3883 . The mechanism in the remaining @entity1 was unknown. @entity12119 , particularly the intravenous preparation, in invaluable in treating severe @entity1793 but should be used with caution in @entity1 with @entity409 . @entity1 receiving intravenous @entity12119 should be given the oral form of the drug as soon as their clinical condition permits.
